期刊文献+

慢性心力衰竭患者脂蛋白相关磷脂酶A2与超敏肌钙蛋白T、心功能的相关性 被引量:12

Correlation among lipoprotein associated phospholipase A2,hypersensitive troponin T and heart function in patients with chronic heart failure
下载PDF
导出
摘要 目的阐明慢性心力衰竭患者血浆脂蛋白相关磷脂酶A2水平与超敏肌钙蛋白T、心力衰竭严重程度的相关性。方法收集2016年1月至2018年10月于粤北人民医院心血管内科初次收治的病因为心脏瓣膜病、缺血性心肌病、扩张型心肌病的慢性心力衰竭患者,年龄50~75岁。最终共收集到慢性心力衰竭NYHAⅣ级患者88例,NYHAⅢ级患者82例,NYHAⅡ级患者48例,对照组92例。检测各组患者血浆脂蛋白相关磷脂酶A2、超敏肌钙蛋白T、氨基末端脑钠肽前体水平及左室射血分数。结果与对照组相比,慢性心力衰竭组患者血浆脂蛋白相关磷脂酶A2、超敏肌钙蛋白T水平均明显升高,且心功能Ⅳ组高于心功能Ⅲ级组,心功能Ⅲ级组高于心功能Ⅱ级组,差异具有统计学意义(P<0.05)。血浆脂蛋白相关磷脂酶A2水平与超敏肌钙蛋白T水平呈正相关(r=0.589;P<0.001)、与氨基末端脑钠肽前体水平呈正相关(r=0.693;P<0.001)、与左室射血分数呈负相关(r=-0.535;P<0.001)。结论血浆脂蛋白相关磷脂酶A2水平与超敏肌钙蛋白T水平和心力衰竭严重程度呈正相关。血浆脂蛋白相关磷脂酶A2可作为慢性心力衰竭患者新的炎症标志物,为心力衰竭的严重程度判断及发病机制提供新的依据。 Objective To explain the correlation among the level of plasma lipoprotein associated phospholipase A2(Lp-PLA2),hypersensitive troponin T(hs-TnT)and severity of heart failure in patients with chronic heart failure(CHF).Methods CHF patients(aged from 50 to 75)hospitalized due to valvular disease,ischemic cardiomyopathy and dilated cardiomyopathy(DCM)were chosen from Jan.2016 to Oct.2018.There were finally 88 patients with CHF-NYHAⅣ(NYHAⅣgroup),82 with CHF-NYHAⅢ(NYHAⅢgroup),48 with CHF-NYHAⅡ(NYHAⅡgroup),and 92 with normal heart function(control group).The levels of Lp-PLA2,hs-TnT,NT-proBNP and left ventricular ejection fraction(LVEF)were detected in all groups.Results Compared with control group,the levels of Lp-PLA2 and hs-TnT increased significantly in all NYHA groups,and those were higher in NYHAⅣgroup than those in NYHAⅢgroup,and were higher in NYHAⅢgroup than those in NYHAⅡgroup(P<0.05).The level of Lp-PLA2 was positively correlated to level of hs-TnT(r=0.589,P<0.001),positively correlated to level of NT-proBNP(r=0.693,P<0.001),and negatively correlated to LVEF(r=-0.535,P<0.001).Conclusion Plasma Lp-PLA2 level is positively correlated with hs-TnT level and the severity of heart function.Lp-PLA2 can be taken as a new inflammatory indicator in CHF patients,and provides new evidences for judging the severity and pathogenesis of heart failure.
作者 陈泽芳 尹建国 黄志航 李国达 徐凯珍 Chen Zefang;Yin Jianguo;Huang Zhihang;Li Guoda;Xu Kaizhen(Department of Cardiovascular Medicine,Yuebei People's Hospital,Guangdong Province,Shaoguan 512000,China;不详)
出处 《中国循证心血管医学杂志》 2020年第3期308-311,共4页 Chinese Journal of Evidence-Based Cardiovascular Medicine
基金 广东省韶关市卫生和计生科研项目(Y18060)。
关键词 慢性心力衰竭 脂蛋白相关磷脂酶A2 超敏肌钙蛋白T 氨基末端脑钠肽前体 射血分数 Chronic heart failure Lipoprotein associated phospholipase A2 Hypersensitive troponin T N-terminal pro-brain natriuretic peptide Ejection fraction
  • 相关文献

参考文献4

二级参考文献24

  • 1J Am Coll Cardiol,张伟丽.CRP与斑块破裂有关[J].中国分子心脏病学杂志,2005,5(3):546-546. 被引量:78
  • 2Zalewski A, Macphee C. Role of lipoprotein-associated phospholipase A2 in atherosclerosis biology, epidemiology, and possible therapeutic target. Arterioscler Thromb Vasc Biol 2005; 25: 923-931. 被引量:1
  • 3Waxman S, Ishibashi F, Muller JE. Detection and treatment of vulnerable plaques and vulnerable patients: novel approaches to prevention of coronary events. Circulation 2006; 114: 2390-2411. 被引量:1
  • 4Kolodgie FD, Burke AP, Skorija KS, Ladich E, Kutys R, Makuria AT, et al. Lipoprotein-associated phospholipase A2 protein expression in the natural progression of human coronary atherosclerosis. Arterioscler Thromb Vase Biol 2006; 26: 2523-2529. 被引量:1
  • 5Wilensky RL, Shi Y, Mohler ER 3rd, Hamamdzic D, Burgert ME, Li J, et al. Inhibition of lipoprotein-associated phospholipase A2 reduces complex coronary atherosclerotic plaque development. Nat Med 2008; 14: 1059-1066. 被引量:1
  • 6Corson MA, Jones PH, Davidson MH. Review of the evidence for the clinical utility of lipoprotein-associated phospholipase A2 as a cardiovascular risk marker. Am J Cardiol 2008; 101 (12A): 41F-50E. 被引量:1
  • 7Koenig W, Khuseyinova N. Lipoprotein-associated and secretory phospholipase A2 in cardiovascular disease: the epidemiological evidence. Cardiovasc Drugs Ther 2009; 23: 85-92. 被引量:1
  • 8Anderson JL. Lipoprotein-associated phospholipase A2: an independent predictor of coronary artery disease events in primary and secondary prevention. Am J Cardiol 2008; 101 (12A): 23F-33E. 被引量:1
  • 9The TIMI Study Group. The thrombolysis in myocardial infarction (TIMI) trial. N Engl J Med 1985; 312: 932-936. 被引量:1
  • 10Fujii K, Kobayashi Y, Mintz GS, Takebayashi H, Dangas G, Moussa I, et al. Intravascular ultrasound assessment of ulcerated ruptured plaques: a comparison of culprit and nonculprit lesions of patients with acute coronary syndromes and lesions in patients without acute coronary syndromes. Circulation 2003; 108: 2473-2478. 被引量:1

共引文献4718

同被引文献171

引证文献12

二级引证文献27

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部